The Efficacy of Conventional FPLV Vaccines against CPV
The study of an attenuated live FPLV vaccine for CPV-2b infection has shown that vaccinated SPF cats are protected from challenge with CPV-2b at 2 weeks after vaccination . A cross-neutralization study of the antibodies induced by an inactivated FPLV vaccine demonstrated that the vaccinated cats actually develop neutralizing antibodies against CPV-2a, 2b, and 2c as well as FPLV . These data indicate that commercially available FPLV vaccines can be used for protection against CPVs, at least in the short term. However, antibody titers induced by a FPLV vaccine are significantly lower against CPVs than FPLV . Indeed, CPV infection was observed in the cheetahs vaccinated with a killed FPLV vaccine . We therefore suggest that FPLV vaccines are not always sufficient to protect cats from CPV infection in the long term. Steinel et al.  have proposed the need for inactivated vaccines that use CPV-2a or 2b for cats. CPV-2a/2b-based vaccines are expected to protect cats more efficiently from CPV infection than conventional FPLV vaccines. Recently, Nakamura et al. reported that cats experimentally infected with CPV-2a develop high titers of neutralizing antibodies against CPV-2a and 2b but show relatively low titers against FPLV . Thus, like FPLV vaccines for CPV infection, CPV-2a/2b-based vaccines may be less efficient for FPLV infection, which would be a major concern. Interestingly, CPV-2c-infected cats showed similar neutralization antibody titers against FPLV, CPV-2a, and 2b as well as CPV-2c . An inactivated CPV-2c-based vaccine for cats could be a promising vaccine candidate against both CPV and FPLV infection.
Emerging Infectious Diseases. 2002;8(4) © 2002 Centers for Disease Control and Prevention (CDC)
Cite this: Feline Host Range of Canine parvovirus: Recent Emergence of New Antigenic Types in Cats - Medscape - Apr 01, 2002.